Related Experiment Video

Updated: Jun 7, 2026

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
08:42

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China

Published on: February 11, 2022

[Effect of dexamethasone on atrial fibrillation after cardiac surgery: a meta-analysis]

Kang Yi1, Jin-Hui Tian, Bin Zhang

  • 1The Evidence-based Medicine Center of Lanzhou University, Lanzhou 730000, China.

Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]
|November 9, 2010
PubMed

Insights

Preoperative dexamethasone may reduce the incidence of postoperative atrial fibrillation after cardiac surgery. However, this study found no significant effect on reducing post-operative mortality, requiring further clinical validation.

Area of Science:

  • Cardiology
  • Anesthesiology
  • Pharmacology

Background:

  • Postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery.
  • Dexamethasone, a corticosteroid, has shown potential anti-inflammatory effects that might mitigate POAF.

Purpose of the Study:

  • To evaluate the efficacy of preoperative dexamethasone in preventing POAF.
  • To assess the impact of dexamethasone on postoperative mortality.

Main Methods:

  • Systematic review and meta-analysis of four randomized controlled trials.
  • Searches conducted across multiple databases including PubMed, EMBASE, and Cochrane Library.
  • Data synthesis performed using RevMan5.0 software.

Main Results:

  • Meta-analysis of 667 participants indicated a statistically significant reduction in POAF with dexamethasone (RR = 0.6, P = 0.02).
  • Dexamethasone did not demonstrate a significant reduction in postoperative mortality (RR = 0.79, P = 0.66).

Conclusions:

  • Preoperative dexamethasone appears to reduce the incidence of atrial fibrillation following cardiac surgery.
  • Further clinical studies are needed to confirm effectiveness due to limitations like small sample size and unclear dosing protocols.
Abstract

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...